| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10046482 | HBV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
| TVIS10057601 | HBV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
| TVIS30021024 | HIV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BTK |
|---|---|
| DrugBank ID | DB11703 |
| Drug Name | Acalabrutinib |
| Target ID | BE0001284 |
| UniProt ID | Q06187 |
| Regulation Type | inhibitor |
| PubMed IDs | 31028669; 32736596; 31591468; 33689480; 34209188 |
| Citations | Bond DA, Woyach JA: Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. doi: 10.1007/s11899-019-00512-0.@@Wilkinson T, Dixon R, Page C, Carroll M, Griffiths G, Ho LP, De Soyza A, Felton T, Lewis KE, Phekoo K, Chalmers JD, Gordon A, McGarvey L, Doherty J, Read RC, Shankar-Hari M, Martinez-Alier N, O'Kelly M, Duncan G, Walles R, Sykes J, Summers C, Singh D: ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691. doi: 10.1186/s13063-020-04584-9.@@Castillo JJ, Treon SP: What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7.@@Zheng TJ, Lofurno ER, Melrose AR, Lakshmanan HHS, Pang J, Phillips KG, Fallon ME, Kohs TCL, Ngo ATP, Shatzel JJ, Hinds MT, McCarty OJT, Aslan JE: Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. Am J Physiol Cell Physiol. 2021 May 1;320(5):C902-C915. doi: 10.1152/ajpcell.00296.2020. Epub 2021 Mar 10.@@Kaliamurthi S, Selvaraj G, Selvaraj C, Singh SK, Wei DQ, Peslherbe GH: Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19. Int J Mol Sci. 2021 Jun 30;22(13). pii: ijms22137071. doi: 10.3390/ijms22137071. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylimidazoles |
| SMILES | CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3707348 |
